Ador Diagnostics is a pioneering medical technology company focused on revolutionizing infectious disease diagnostics. They are developing the Ador Detection Platform, utilizing their proprietary NATflow™ (Nanoparticle-Activated Tflow) technology, to provide rapid, highly accurate, and multiplexed molecular testing at the point-of-care. Their goal is to empower clinicians with timely diagnostic information to improve patient outcomes and combat antimicrobial resistance by enabling targeted therapy. Ador's system aims to deliver lab-quality results in minutes, directly where patient care is administered.
The headquarters serves as the primary center for research and development, manufacturing, corporate strategy, and global operations management.
The facility likely includes state-of-the-art R&D laboratories for molecular biology and engineering, cleanroom facilities for device assembly, and modern office spaces designed for collaboration.
The work culture at Ador Diagnostics's HQ is likely dynamic, innovative, and research-driven, fostering collaboration between scientific, engineering, and business teams to advance their diagnostic platform.
The Caesarea headquarters is central to Ador's mission, housing the core intellectual property development, product refinement, and strategic planning that drives the company's growth and market penetration.
While headquartered in Israel, Ador Diagnostics has a global outlook, particularly focusing on key markets like the United States and Europe for its diagnostic solutions. Their global functions include establishing clinical trial sites, seeking regulatory approvals (e.g., FDA, CE-IVD), building commercial partnerships, and preparing for international product launches. They aim to make their NATflow™ technology accessible worldwide to address infectious diseases globally.
HaEshel St 7
Caesarea
Caesarea Industrial Park North
Israel
Address: Specific street address not publicly listed, operations may be through partners or a small representative office.
To facilitate engagement with the U.S. healthcare ecosystem, including key opinion leaders, research institutions, and potential commercial partners, as well as to navigate the U.S. regulatory landscape.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ADOR Diagnostics' leadership includes:
ADOR Diagnostics has been backed by several prominent investors over the years, including:
Based on publicly available information, Ador Diagnostics has maintained a relatively stable core executive team. Any recent changes within the last 12 months, if not widely publicized, would be internal. Jonathan Roger's appointment as CFO appears to be within the last 1-2 years, representing a significant addition to the leadership team.
Discover the tools ADOR Diagnostics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Ador Diagnostics likely uses common corporate email formats. Based on patterns seen in similar tech companies, emails often combine first name, last name, or initials with the @ador.com domain.
[firstinitial][last]@ador.com or [first].[last]@ador.com or [first]@ador.com
Format
jkruse@ador.com (example for Jobst Kruse)
Example
80%
Success rate
PR Newswire • March 7, 2024
Ador Diagnostics announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Ador NATlab™ System and the Ador Respiratory Panel (RUO). This clearance marks a significant milestone for the company, paving the way for the use of its rapid molecular diagnostic platform in the U.S....more
ador.com (Company News) • September 7, 2023
Ador Diagnostics announced the appointment of Jonathan Roger as its new Chief Financial Officer. Jonathan brings a wealth of experience in financial management and strategy within the life sciences and technology sectors, which will be invaluable as Ador continues to grow and commercialize its innovative diagnostic solutions....more
GlobeNewswire • January 10, 2023
Ador Diagnostics announced the successful closure of a $20 million funding round. The investment, led by existing and new prominent global investors, will be used to accelerate the development and commercialization of its NATflow™ technology for rapid, point-of-care molecular diagnostics....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ADOR Diagnostics, are just a search away.